Dimethyl fumarate in relapsing–remitting multiple sclerosis: rationale, mechanisms of action, pharmacokinetics, efficacy and safety
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Dimethyl fumarate in relapsing–remitting multiple sclerosis: rationale, mechanisms of action, pharmacokinetics, efficacy and safety
Authors
Keywords
-
Journal
Expert Review of Neurotherapeutics
Volume 15, Issue 4, Pages 339-346
Publisher
Informa UK Limited
Online
2015-03-24
DOI
10.1586/14737175.2015.1025755
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Dimethyl Fumarate (Tecfidera)
- (2014) Jineane V. Venci et al. ANNALS OF PHARMACOTHERAPY
- Current and Future Therapies Targeting the Immune System in Multiple Sclerosis
- (2014) Verena Loleit et al. CURRENT PHARMACEUTICAL BIOTECHNOLOGY
- Mode of action and clinical studies with fumarates in multiple sclerosis
- (2014) Anke Salmen et al. EXPERIMENTAL NEUROLOGY
- Tolerability and Pharmacokinetics of Delayed-Release Dimethyl Fumarate Administered With and Without Aspirin in Healthy Volunteers
- (2013) Sarah I. Sheikh et al. CLINICAL THERAPEUTICS
- Oral BG-12 (dimethyl fumarate) for relapsing–remitting multiple sclerosis: a review of DEFINE and CONFIRM
- (2013) Eva Havrdova et al. EXPERT OPINION ON PHARMACOTHERAPY
- Manufacturer's Response to Case Reports of PML
- (2013) Marianne T. Sweetser et al. NEW ENGLAND JOURNAL OF MEDICINE
- PML in a Patient Treated with Fumaric Acid
- (2013) Ummehan Ermis et al. NEW ENGLAND JOURNAL OF MEDICINE
- Progressive multifocal leukoencephalopathy associated with immunosuppressive therapy in rheumatic diseases: Evolving role of biologic therapies
- (2012) Eamonn S. Molloy et al. ARTHRITIS AND RHEUMATISM
- Mechanisms of Oxidative Glutamate Toxicity: The Glutamate/Cystine Antiporter System xc¯ as a Neuroprotective Drug Target
- (2012) Philipp Albrecht et al. CNS & Neurological Disorders-Drug Targets
- Mechanisms of Oxidative Damage in Multiple Sclerosis and Neurodegenerative Diseases: Therapeutic Modulation via Fumaric Acid Esters
- (2012) De-Hyung Lee et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Dimethyl Fumarate Inhibits Dendritic Cell Maturation via Nuclear Factor κB (NF-κB) and Extracellular Signal-regulated Kinase 1 and 2 (ERK1/2) and Mitogen Stress-activated Kinase 1 (MSK1) Signaling
- (2012) Haiyan Peng et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis
- (2012) Robert J. Fox et al. NEW ENGLAND JOURNAL OF MEDICINE
- Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis
- (2012) Ralf Gold et al. NEW ENGLAND JOURNAL OF MEDICINE
- Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway
- (2011) Ralf A. Linker et al. BRAIN
- Fumarates improve psoriasis and multiple sclerosis by inducing type II dendritic cells
- (2011) Kamran Ghoreschi et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Suppression of VEGFR2 Expression in Human Endothelial Cells by Dimethylfumarate Treatment: Evidence for Anti-Angiogenic Action
- (2011) Markus Meissner et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Oral treatment for multiple sclerosis
- (2011) Joep Killestein et al. LANCET NEUROLOGY
- Phytochemical Induction of Cell Cycle Arrest by Glutathione Oxidation and Reversal by N-Acetylcysteine in Human Colon Carcinoma Cells
- (2009) R. Y. Odom et al. NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL
- Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study
- (2008) Ludwig Kappos et al. LANCET
- Temporal trends in the incidence of multiple sclerosis: A systematic review
- (2008) A. Alonso et al. NEUROLOGY
- B-Cell Depletion with Rituximab in Relapsing–Remitting Multiple Sclerosis
- (2008) Stephen L. Hauser et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started